EBIT: Income before interest and taxes.
enGene Therapeutics Inc (ENGN) had EBIT of $-31.18M for the most recently reported fiscal quarter, ending 2026-01-31.
| Income Statement Financials | |
-- |
|
$-29.75M |
|
-- |
|
-- |
|
$31.18M |
|
$-31.18M |
|
$1.43M |
|
$-29.75M |
|
$-29.75M |
|
$-29.75M |
|
$-29.75M |
|
$-29.75M |
|
$-29.75M |
|
|
EBIT |
$-31.18M |
$-31.59M |
|
67.26M |
|
67.26M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$289.22M |
|
$2.44M |
|
$47.90M |
|
$337.11M |
|
$24.61M |
|
$24.74M |
|
$30.96M |
|
$55.57M |
|
$281.55M |
|
$281.55M |
|
$281.55M |
|
66.99M |
|
| Cash Flow Statement Financials | |
$-28.90M |
|
$-126.30M |
|
$141.66M |
|
$50.15M |
|
$36.61M |
|
$-13.54M |
|
$2.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.75 |
|
-- |
|
-- |
|
0.08 |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.57% |
|
-10.57% |
|
-8.83% |
|
-9.71% |
|
$4.20 |
|
$-0.43 |
|
$-0.43 |
|